NCT07622290Not yet recruitingPhase 3
Metformin Treatment for Children With Obesity-associated Asthma
The Role of Metformin in Asthma Control in Obese/Overweight Children, a Randomized Placebo Controlled Clinical Trial
Source: ClinicalTrials.gov · Last updated 3 Jun 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if metformin can improve asthma control in overweight and obese children with mild, moderate, or severe asthma. It will also evaluate the safety and metabolic effects of metformin in this population. The main questions the study aims to answer are: 1\) Does metformin improve asthma control, as measured by the Asthma Control Test (ACT) score? 2) Does metformin improve lung function, reduce asthma exacerbations, and improve metabolic and inflammatory markers in overweight/obese children with asthma? Researchers will compare metformin with a placebo (a look-alike substance that contains no active drug) to see if metformin improves asthma outcomes in overweight/obese children with asthma. Participants will take either metformin or a placebo in addition to their standard asthma treatment during the study period. They will attend scheduled clinic visits for asthma assessments, lung function testing, and safety monitoring. Blood, stool, and saliva samples, along with clinical information, will be collected from participants to assess asthma control, and markers related to metabolism and inflammation. Participants will also complete asthma control questionnaires and report medication use and asthma symptoms throughout the study period.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 182 (estimated)
- First submitted
- 12 May 2026
- Start date
- Jun 2026
- Primary completion date
- Aug 2027
- Lead sponsor
- Prof Ibrahim Janahi
- NCT number
- NCT07622290
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 182
- From Jun 2026 to the primary completion date, Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Symptomatic or previously symptomatic congenital heart disease
- Taking metformin or GLP1 medication less than 3 months of the recruitment date
Other illness
- Non-asthma chronic lung disease
- Inflammatory bowel disease
- Syndromic disorders (e.g. Down's syndrome, Turner's syndrome)
- Neuromuscular disorders
- Swallowing disorders
- Ongoing treatment for cancer
- Children diagnosed with type-1 diabetes
Other
- Broncho-pulmonary dysplasia
- Inborn errors of metabolism
- Craniofacial abnormalities
- Primary thoracic cage abnormalities
- Secondary endocrinopathies causing obesity
- Renal complications
Who the study is looking for
- Participant who are capable of giving assent and parentral consent
- Male/Female participant aged between10-17 years old,
- overweight/obese children (Overweight and obesity are defined as BMI equal and above the 85th percentile, and BMI above the 95th percentile for age and sex, respectively).
- Diagnosed with mild persistent, moderate persistent /severe asthma based on GINA guidelines within the 6 months prior to the recruitment date and having ACT score \< 20, residing in Qatar
- Partcipants on standard asthma therapy for at least the last 6 months prior to the recruitment
- Participant who are currently not taking part in any other interventional study
Age in the registry: 10 years to 17 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sidra Medicine Coordinator of this site? Confirm its status | Doha | Qatar | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.